SDS Optic S.A. received 3 million euros from the European Investment Bank

The receipt of the first tranche confirms the fulfillment of all conditions specified in the financing agreement signed in October 2023. This includes obtaining the ISO 13485 certificate issued by the notified body TÜV NORD GROUP, the completion of the first part of clinical trials for the diagnostic microsensor in HER2 breast cancer, and securing 1 million euros from a share issuance in February 2023.

Mateusz Sagan, Chief Operating and Business Development Officer: "Receiving the first tranche of EIB financing marks the culmination of a long and highly complex process of due diligence, negotiating contract terms, a series of meetings with legal teams, and an extremely intricate administrative process leading to the disbursement of funds. The entire process turned out to be much more complicated and time-consuming than we had all anticipated, and the level of complexity of many issues was even greater than that of traditional M&A processes. This makes us all the more pleased to have received the first tranche of funds from the EIB. Thanks to this, we can return to the projects and work we had committed to our shareholders, which unfortunately had been delayed due to the volume and complexity of the tasks required to secure EIB funding. Receiving the EIB funds allows us to significantly scale our activities and accelerate work in many areas, including corporate and research & development initiatives. We are placing a strong emphasis on scaling the inPROBE platform, expanding target markets, and strengthening hardware infrastructure. The company is ready for rapid growth and innovation. The five-year development project supported by the EIB positions SDS Optic in a completely different league, paving the way for greater scalability and market penetration. This is of immense importance in the commercialization process of our technology."

See the company's video commentary

The financial support from the EIB not only confirms the potential of SDS Optic's innovative approach but also positions the company within an elite group of firms that have undergone a thorough evaluation by the European Investment Bank. In a competitive environment, SDS Optic stands out as one of the few Polish companies to have secured such prestigious funding. Access to capital from the European Investment Bank provides SDS Optic with financial stability, allowing it to focus on its core mission and project execution without the immediate need for public offerings or issuances. This strategic decision not only minimizes financial costs but also enables the company to concentrate on research and development. The five-year financial plan provided by the EIB marks a turning point, reshaping SDS Optic S.A.'s operational and development strategies for the coming years.

Marcin Staniszewski, President of the Management Board of SDS Optic S.A.: "The first tranche received from the European Investment Bank represents a significant milestone for SDS Optic. It not only confirms our innovative approach but also allows us to accelerate our growth. We are already recognized globally, and EIB financing significantly enhances our ability to reach new investors, buyers, and partners. SDS Optic S.A.'s technological projects, which integrate exceptionally complex scientific disciplines, are characterized by variability, an iterative development process, and the frequent need for rapid adaptation to the environment. The capital obtained from the EIB will enable the company to make decisions more easily based on experience and knowledge gained from ongoing research, providing a necessary source of funding—even if the company decides on additional work required before final commercialization."

With the support of the EIB, SDS Optic is ready to embark on a new phase of growth and innovation, pursuing its mission of developing life- and health-saving technologies and shaping the future landscape of medical and biotechnology solutions based on photonic technologies.

ESPI Announcement: